|Bid||25.18 x 1300|
|Ask||25.34 x 800|
|Day's Range||25.25 - 25.43|
|52 Week Range||9.59 - 29.55|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.28|
Investing in biotech stocks has its up days and its down days. For investors in Biogen (NASDAQ:BIIB) -- and more importantly millions of Alzheimer's patients around the world -- yesterday was a down day. On Thursday, Biogen stock plunged more than 30% on the cancelation of stage 3 clinical trials for a blockbuster Alzheimer's medication.Source: Shutterstock The massive drop was truly an unsettling surprise for BIIB shareholders as the drug was seen as a multi-billion blockbuster and game-changing medication for treating the disease. It really did come out of nowhere. The question now is whether to cut bait or fish. Was the drop enough to get investors excited about Biogen stock again?Given its huge revenue drivers, now cheaper price and still large pipeline, the answer is a resounding yes.InvestorPlace - Stock Market News, Stock Advice & Trading Tips What Happened at Biogen?Biotech stocks trade based on expectations. Something positive happens and then investors send the stock skyward and wait for the next big event to occur. It's all about what's coming down the runway. Expectations build upon that. This is true for large biotech stocks as well.For Biogen, the expectation build-up had to do with its Alzheimer's drug candidate aducanumab. The drug was in the class of monoclonal antibody medications. Basically, aducanumab was designed to break down the beta-amyloid plaques that can build up in the brain. These amyloids interfere with communication between brain cells and cause Alzheimer's and mild dementia. Back in 2014, BIIB saw some serious success with aducanumab during an early-stage study. It actually seemed to reduce the build-ups. * 7 Retail Stocks That Will Continue to Rebound in 2019 Thanks to this very positive early trial, Biogen decided to skip over smaller phase 2 studies and move the medication into larger and more advanced stage 3 testing. The idea was that Biogen could skip through the process and land a Food and Drug Administration (FDA) approval much faster. And there was a good chance for that considering how well it did early on.For Biogen stock, this would have been a major win on several fronts.For starters, there have not been any new Alzheimer's therapies approved in more than 15 years. meanwhile, the Alzheimer's Association pegs more than 5.8 million Americans currently living with the disease. Biogen was looking at a potential blockbuster with huge revenue implications. And it potentially needs that revenue to fill the coming declines in its multiple sclerosis portfolio.Unfortunately for BIIB and Alzheimer's patients, they'll have to wait a bit longer.Biogen and its partner Eisai reported that they would discontinue two late-stage trials for the drug after doing a futility analysis. An independent data-monitoring committee came to the conclusion that aducanumab was "unlikely to meet the primary endpoints" in either study.With expectations for the company to score a major blockbuster, investors abandoned Biogen stock. BIIB fell 30% -- or $90 per share -- and had its worst day of trading in nearly 2 decades. Biogen Stock May Be Worth SnaggingBiogen stock's loss was tremendous and goes to show just how much investors were valuing the drug as part of BIIB's future prospects. But perhaps, investors have taken Biogen down too much on the news.For starters, Biogen isn't a fly by night clinical-stage biotech stock. It's just the opposite. The firm has a portfolio of some pretty big blockbusters already. Thanks to winners like Spinraza and Tysabri, BIIB's portfolio managed to see a 10% jump in sales last year to more than $13.45 billion. Moreover, that portfolio managed to generate more than $5.3 billion in free cash flows and impressive earnings.And it's using those profits in a smart way. The key is that Biogen has been building a full pipeline to create a multi-franchise neurology portfolio. This includes its recent buyout of retinal degeneration specialist Nightstar Therapeutics (NASDAQ:NITE). So yes, losing Alzheimer's does stink, but the biotech's rich pipeline and cash flows give it plenty of wiggle room to buy or develop a pipeline. According to CFO Jeff Capello, adding up cash flows, cash on hand and its ability to leverage up and "you get a $37 billion number, which gives us a lot of capacity to add to the business."It's a song and dance we've heard plenty of times before. But Biogen has the firepower to make it work. It can buy a pipeline successfully.For that pipeline potential and drugs already producing revenues, Biogen stock is going for dirt cheap. After yesterday's 30% haircut, you can now snag the biotech firm at just 8.7x free cash flows and a trailing P/E of just 10.50. That's bargain-basement pricing for a biotech leader. For example, Amgen (NASDAQ:AMGN) can be had for a P/E of 14, while Gilead Sciences (NASDAQ:GILD) is closer to 16. Nibbling at Biogen StockGiven the steep drop and perhaps overreaction that sent Biogen stock into extreme value territory, investors with a longer-term timeline may want to consider snagging some of the firm's shares. * 7 Beaten-Up Stocks to Buy as They Reverse Course The lost of the Alzheimer's drug does hurt, but BIIB still has plenty in the tank to get it through. And with today's valuations, there's a decent margin of safety associated with shares. The time to start buying could be now.Disclosure: At the time of writing, Aaron Levitt held a long position in the iShares NASDAQ Biotechnology Index (IBB) -which holds GILD, BIIB and AMGN. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks That Will Continue to Rebound in 2019 * 5 Stocks To Buy for the Happiest Employees * 7 ETFs for a Millennial Portfolio Compare Brokers The post Biogen Stock Fell Too Far on Unfortunate News appeared first on InvestorPlace.
HENDERSON, NV / ACCESSWIRE / March 8, 2019 / The past few weeks have been busy with big bio taking over smaller biotechs developing novel therapies. Roche (RHHBY) said it would spend $4.8 billion in a ...
Biogen's pending acquisition of gene therapy player Nightstar Therapeutics only offers a "modest pipeline boost," an analyst said Tuesday. Nightstar is working on therapies for eye diseases.
Biogen Inc (NASDAQ: BIIB ) announced Monday a deal to buy gene therapy biotech Nightstar Therapeutics PLC (NASDAQ: NITE ) for $800 million. The Analysts Baird analyst Brian Skorney maintained a Neutral ...
Stocks that moved substantially or traded heavily on Monday: Children's Place Inc., down $9.78 to $84.82 The children's clothing retailer reported weak fourth-quarter results and issued a weak forecast. ...
Nightstar Therapeutics soared early Monday after Biogen pledged to spend $800 million to buy the gene therapy firm. The smaller biotech is working on gene therapies in rare eye diseases.
Nightstar Therapeutics stock was soaring on Monday following news that Biogen (NASDAQ:BIIB) is acquiring it.Source: Biogen via YouTubeThe deal will have Biogen spending a total of $877 million to acquire Nightstar Therapeutics (NASDAQ:NITE). This will have the company paying $25.50 in cash for each share of Nightstar Therapeutics stock.The offer price of $25.50 per share for Nightstar Therapeutics stock represents a 70% premium to the stock's 30 trading day volume-weighted average price. It is also a 68% premium over the stock's closing price from Friday.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBiogen notes that all issued and to be issued shares of Nightstar Therapeutics stock will be acquired by Tungsten Bidco Limited. This is a newly-incorporated company and wholly-owned subsidiary of BIIB."I am proud of Nightstar's achievements, delivering two proof-of-concept programs and building a world class organisation," Chris Hollowood, Chairman of Nightstar Therapeutics, said in a statement. "We look forward to seeing the next chapter of Nightstar's journey under Biogen's ownership, as it works to achieve its ultimate ambition of delivering transformational treatments to patients."Biogen and Nightstar Therapeutics are expecting the acquisition deal to close during mid-2019. However, it will first have to get regulatory approval and complete other customary closing conditions. Among these is approval from holders of Nightstar Therapeutics stock for the deal. The acquisition does not need approval from shareholders of BIIB. * 7 Top-Rated Stocks to Buy for March Nightstar Therapeutics is getting its financial advice for the deal from Centerview Partners and Jefferies LLC. The company's legal advice concerning the matter is coming from Arps, Slate, Meagher & Flom LLP.Nite stock was up 66% and BIIB stock was down 2% as of noon Monday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Retail Stocks Ready to Break Out * 7 Strong Buy Stocks the Street Loves * 10 Best Stocks to Buy and Hold Forever As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post NITE, BIIB: Nightstar Therapeutics Stock Soars on Biogen Buy appeared first on InvestorPlace.
Becoming the latest players in the health care space to consolidate, Biogen Inc. (BIIB) announced on Monday morning it is buying London-based gene therapy company Nightstar Therapeutics PLC (NITE) for $800 million. According to the terms of the all-cash deal, the Cambridge, Massachusetts-based biotech company will pay $25.50 per share of Nightstar, which represents a 68% premium to its closing price of $15.16 on Friday. Warning! GuruFocus has detected 5 Warning Sign with TSX:ATD.B. Click here to check it out.
Analysts including Jefferies’s Michael Yee said Biogen still needs to do more to move the needle. Nightstar jumped 66 percent to $25.18, just shy of the $25.50-a-share offer. The acquisition comes just a week after Roche Holding AG made a $4.8 billion bid for Spark Therapeutics Inc. Nightstar’s pipeline includes a pair of late-stage treatment candidates for rare inherited retinal diseases.
Nightstar shares were up 66% to $25.16 in trading Monday. Biogen's offer for Nighstar is $25.50 a share. Nightstar makes gene therapy treatments for choroideremia, a rare, inherated eye disease that leads to blindness.
Biogen Inc (NASDAQ: BIIB ) is the latest biotech company to jump onto the gene therapy bandwagon . What To Know Biogen, which focuses on developing therapies for neurological and neurodegenerative diseases, ...
Shares of Nightstar Therapeutics PLC rocketed 67% to pace all premarket gainers in very active trade, after the gene therapy company agreed to be acquired by Biogen Inc. in a cash deal valued at about $877 million. Trading volume in Nightstar spiked to over 570,000 shares, compared with the full-day average of about 71,300 shares. Under terms of the deal, U.K.-based Nightstar shareholders will receive $25.50 for each Nightstar share they own, which represents a 68% premium to Friday's closing price of $15.16. The deal is expected to become effective by mid-year 2019. "This transaction accelerates treatment to patients through Nightstar's key retinal gene therapy programs that modify or halt progression of blindness," said Nightstar Chief Executive David Fellows. Nightstar shares have climbed 15.7% over the past 12 months, while the iShares Nasdaq Biotechnology ETF has gained 5.0% and the S&P 500 has advanced 4.2%.
The all-cash deal, which values Nightstar at around $877 million, hands Biogen a gene therapy for choroideremia, a rare, inherited eye disease that leads to blindness. The treatment is undergoing late-stage clinical trials. Nightstar, which was founded in 2013 based on research at the University of Oxford, also has several earlier-stage gene therapies in its pipeline, all aimed at rare inherited eye disorders.
Biogen Inc said on Monday it will buy Nightstar Therapeutics Plc for about $800 million in cash as the company looks to tap into a potentially lucrative gene therapy market. Biogen's offer of $25.50 per ...
Nightstar Therapeutics plc ("Nightstar") (NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases and Biogen Inc. ("Biogen") are pleased to announce that they have reached agreement on the terms of a recommended acquisition whereby the entire issued and to be issued share capital of Nightstar will be acquired by Tungsten Bidco Limited (a newly-incorporated company and wholly-owned subsidiary of Biogen Switzerland Holdings GmhH (“Bidder”)). It is intended that the Acquisition will be implemented by means of a U.K. Court-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006. Under the terms of the Acquisition, Nightstar Shareholders will be entitled to receive USD 25.50 in cash for each Nightstar Share.
Biotech stocks are a staple among growth investors. The rewards can be staggering - prices on biotechnology shares can literally double overnight - but the risk is just as high. It's not unusual for these stocks to be cut in half or worse if drug-trial data disappoints or a drug application is rejected. Thus, proper due diligence is critical, and that includes tapping the experts for information about these often difficult-to-gauge stocks. Mizuho Securities has recently put out an analyst report highlighting its top biotechnology picks for 2019. And thanks to analyst ranking service TipRanks, we can see that the report's author, Managing Director Difei Yang, has a strong track record of stock recommendations. Yang is ranked in the top 250 out of more than 5,100 tracked analysts. Yang writes, "We favor innovative and ground-breaking therapies in 2019; emerging technologies such as gene therapy and cell therapy could command substantial premiums from large cap pharma/biotech if impressive results are shown in historically difficult-to-treat conditions." As Yang points out, pharma M&A; is off to a strong start in 2019 with a number of blockbuster deals. They include Bristol-Myers Squibb's (BMY) $74 billion acquisition of Celgene (CELG), and Eli Lilly's (LLY) $8 billion buyout of Loxo Oncology (LOXO). "In our view, the transactions underscore the persistent need by large pharma to fuel continued growth and replenish R&D; pipelines via M&A;," she writes. Here are Mizuho's top nine biotech stocks to buy right now. Many of them can stand on their own but look even better as potential buyout targets. ### SEE ALSO: 19 Best Stocks to Buy for 2019 (And 5 to Sell)
During the first half of the fourth quarter the Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by about 4 percentage points as investors worried over the possible ramifications of rising interest rates. The hedge funds and institutional investors we track typically invest more in smaller-cap stocks than an average investor (i.e. […]
Phase 2/3 Expansion Study to Include No-Sham Control Arm in Alignment with FDA Draft Guidance on Development of Gene Therapy Products for Retinal Disorders Preliminary Efficacy.